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Received July 14, 2015; accepted October 6, 2015AbstractBackground: In this article, we aimed to define the clinical, pathological, and surgical factors predicting pulmonary recurrence (PR) and
determining survival after PR in patients with endometrial cancer.
Methods: Thirty-six (2.7%) patients were analyzed who suffered pulmonary failure in the first recurrence out of 1345 patients who had at least
extrafascial hysterectomy plus bilateral salpingo-oophorectomy for endometrial cancer between January 1993 and May 2013. The recurrence
was designated as an isolated PR in cases of the presence of recurrence only in the lung, while it was called a synchronized PR if the patient had
extrapulmonary recurrence in addition to PR.
Results: In the multivariate analysis in the entire cohort, only International Federation of Gynecology and Obstetrics stage was an independent
prognostic factor for PR. Two-year overall survival (OS) was 52% in patients with PR. In the univariate analysis, early International Federation
of Gynecology and Obstetrics stage, absence of lymphatic metastasis, negative lymphovascular space invasion, absence of cervical invasion,
negative adnexal spread, negative peritoneal cytology, negative omental metastasis, adjuvant radiotherapy after initial surgery, isolated PR, and
chemotherapy upon recurrence were associated with improved OS after PR. The OS was 54 months for patients with isolated PR, while it was
10 months for patients who had synchronized PR. Furthermore, OS was 43 months and 13 months for the patients who took chemotherapy and
radiotherapy, respectively.
Conclusion: Advanced stage is associated with PR. If recurrence is only in the lung, survival is better. Systemic treatment after PR is associated
with improved survival. However, multi-center studies are required to standardize the treatment for PR.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Endometrial cancer is the sixth most frequent cancer in
women worldwide and 320,000 women are annually diag-
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).GLOBOCAN data.1 Endometrial cancer is usually diagnosed
in the early stages; however, 20% of patients have extrauterine
disease.2 The 5-year overall survival (OS) rate is above 80%
for patients in the early stages.3 Recurrence develops in
11e13% of all patients with endometrial cancer in the first
2 years following initial treatment, depending on the clinical
factors, stage, previous surgery, and pathological factors.4e6 In
the presence of poor prognostic factors, recurrence is observed
in up to 60% of the patients.7e9 Additionally, extrapelvic
failure is detected in >75% of the patients with
recurrence.6,10,11sevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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tasis, and pulmonary metastasis is primarily the result of
hematogeneous spread. Pulmonary failure was reported to be
observed in 1.9e9% of patients with first recurrence.11e17
There is limited data about the factors predicting pulmonary
recurrence (PR). However, PR was reported to be associated
with Stage IV disease and deep myometrial invasion.15 Earlier
reports stated that PR was associated with poor prognosis. In
these reports, 75% of patients with PR were shown to expire
from cancer in the 1st year.14 However, in a recent paper,
patients with isolated lung metastasis that was 2 cm and low
grade were detected to have 98-months OS following recur-
rence.16 Additionally, the 5-year OS of patients with endo-
metrial cancer who had pulmonary metastasectomy after the
initial recurrence was reported to be up to 76%.18e21
The factors predisposing patients to PR, how PR pro-
gresses, and what its treatment should be have not been clar-
ified. The data regarding PR in endometrial cancer is limited
and it is not without limitations. Usually, PR was included in
distant recurrences in previous reports and not analyzed
separately. Patients with sarcomas in addition to epithelial
tumors were generally included or patients with endometrial
cancer were evaluated with patients who had cancer of other
primary sites in those reports.
In the present study, we aimed to define the clinical,
pathological, and surgical factors predicting PR and deter-
mining survival after PR.
2. Methods
A total of 1640 patients with diagnosed epithelial endo-
metrial cancer were treated in our clinic between January 1993
and May 2013. The data of 1413 patients who had at least
extrafascial hysterectomy plus bilateral salpingo-
oophorectomy were obtained from the Gynecological
Oncology Clinic (Ankara, Turkey) electronic database and
patient files. Among these 1413 patients, 68 patients either
were deemed lost to follow-up or died of surgery-related
complications in the early postoperative period. Clinical,
surgical, and pathological data of the remaining 1345 patients
was collected. The patients who had a sarcomatous component
in their final pathology report and who were treated for pul-
monary failure in the second or subsequent recurrences were
not included. The first recurrence was in the lung in 36 of the
1345 patients who were retrospectively evaluated. The entire
cohort was analyzed in order to define the factors determining
PR. In this group, patients with recurrence except PR and
patients who had no recurrence were defined as PR negative
group.
The clinical, surgical, and pathological factors deter-
mining OS in patients with PR (n ¼ 36) were defined. The
recurrence was labeled as an isolated PR in cases of the
presence of recurrence only in the lung, while it was called
synchronized PR if the patient had extrapulmonary recur-
rence in addition to PR. The extent of disease in the lung was
stratified as single pulmonary nodule (1 nodule) and multiple
pulmonary nodules (>1 nodule) according to the number oftumoral nodules in the lung. Recurrence tumor size was
accepted as the largest diameter of the tumor in the lung or
other sites, while the largest diameter of tumor in the lung
was defined as pulmonary tumor size. Disease-free interval
(DFI) was the period between initial surgery and PR, and OS
was defined as the period between PR and death or the last
contact with the patients. Institutional Review Board
(Ankara, Turkey) approval was obtained.
The patients were staged according to the 2009 Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
criteria. Serous, clear cell, and undifferentiated tumors were
accepted as Grade 3 tumors in the pathological evaluation
following initial surgery.
PR and extrapulmonary recurrence was diagnosed by the
clinical and radiological signs obtained from the pelvic and
systemic examination, chest X-ray, abdominopelvic and
thoracic computerized tomography, or magnetic resonance
imaging. Additionally, tissue diagnosis was available in five
patients. The decision of the treatment that would be per-
formed was taken by the gynecologic oncology council. The
status of disease after treatment was evaluated according to the
World Health Organization.22 According to the assessment
made in the 1st month after treatment, we defined clinical
response as the following: (1) complete clinical response:
disappearance of the macroscopic tumor; (2) partial clinical
response: shrinkage over 50% in the macroscopic tumor; (3)
stable disease: macroscopic tumor shrinkage less than 50% or
not less than 25% growth; and (4) progressive disease: > 25%
growth in the macroscopic tumor or macroscopic appearance
of new tumor foci.
Patients who had complete clinical response after the
therapy for recurrence were followed-up every 3 months for
2 years, every 6 months until the 5th year following treatment,
and yearly thereafter. In the follow-up, pelvic examination,
abdominopelvic ultrasonography, complete blood count, and
blood chemistry were performed. At every patient visit, chest
X-ray was performed. Thoracic and/or abdominal computer-
ized tomography was used when there was an abnormality in
the pelvic examination or ultrasonography or chest X-ray or
when there was clinical suspicion. Ca-125 level was utilized in
the follow-up, even though it was not routinely used. The same
follow-up protocol except for the chest X-ray had been per-
formed after the initial treatment that the patients had
received, subsequent to the initial diagnosis of endometrial
cancer. In the follow-up after treatment following the initial
diagnosis of endometrial cancer, chest X-ray was utilized
yearly or more commonly in cases of clinical suspicion such
as the presence of cough and/or dyspnea.
In the entire cohort, the factors determining PR were
compared using Chi-square test. Factors having a p value
< 0.25 in univariate analyses were included as candidate
variables in multivariate analyses with logistic regression
analysis. The isolated PR group was compared with the syn-
chronized PR group with Chi-square test for the categorical
parameters and by analysis of variance table test for contin-
uous parameters. In the PR group, OS estimates were deter-
minated by using the KaplaneMeier method, and survival
Table 2
Factors determining pulmonary recurrence: univariate analysis.
Characteristics Pulmonary
recurrence (%)
p
Age at initial diagnosis (y)a 58 1.9 0.004
>58 5.3
2009 FIGO stage I & II 1.5 <0.0001
III & IV 7.8
Tumor type Endometrioid 2.1 0.001
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determining OS after PR could not be evaluated in multivar-
iate analysis due to the small study population and the inter-
dependence of predictors. Statistical analyses were performed
using SPSS (SPSS Inc., Chicago IL, USA) version 17.0. The
cut-off for statistical significance was set at p < 0.05.
3. ResultsNonendometrioid 6.5
Lymphadenectomy at initial Not performed 0.4 <0.00013.1. Entire cohort
surgery Performed 4.1
No. of removed lymph
nodesa
48 4.4 0.901
>48 4.2
Lymph node metastasis Negative 3 0.003
Positive 7.9
Metastatic lymph node site Isolated pelvic 4.9 0.149
Isolated paraaortic 16.1
Pelvic & paraaortic 7.9
FIGO grade 1 0.6 <0.0001
2 3.6
3 6.8
Depth of myometrial
invasion
1/2 0.9 <0.0001
>1/2 5.8
Lymphovascular space
invasion
Negative 1.3 <0.0001
Positive 5.5
Cervical invasion Negative 2.3 0.056
Positive 5.5
Adnexal metastasis Negative 2.3 <0.0001
Positive 8.8
Peritoneal cytology Negative 2.2 <0.0001
Positive 12.5
Omental metastasis Negative 2 <0.0001
Positive 17
Adjuvant therapy at initial
diagnosis
Not performed 0.5 <0.0001
Performed 5.7
Type of adjuvant therapy Radiotherapy 5.4 0.160
Chemotherapy 8.9
Radiotherapy &
chemotherapyb
1.9
Uterine tumor size (mm)a 40 2.6 0.280
>40 4.2
FIGO ¼ International Federation of Gynecology and Obstetrics.
aThe median age of the 1345 patients was 58 years, ranging
between 23 years and 92 years of age. The median uterine
tumor size was 41 mm (range, 1e335 mm). Two hundred and
fifty-seven patients had Stages III and IV disease. The tumor
type of 1161 patients was endometrioid and 696 patients had
FIGO Grade 1 disease (Table 1). Myometrial invasion was
1/2 in 480 patients and 165 patients had cervical involve-
ment. Lymphovascular space invasion, adnexal involvement,
peritoneal cytology, and omental spread were positive in 311
patients, 92 patients, 64 patients, and 59 patients, respec-
tively. The median lymph node number in the 827 patients
who underwent staging surgery was 48 (range, 2e122) and
190 patients had lymphatic involvement. Overall, a total of
593 patients had adjuvant therapy following surgery. Among
these, 396 patients had only radiotherapy and 112 patients
had only chemotherapy. Furthermore, 83 patients received
both therapies. Additionally, two patients received hormonal
therapy.
Among all cohort with a median follow-up time of
36 months (range, 1e249 months), 162 (12%) patients had
recurrence and 36 (2.7%) had PR. In the univariate analysis,
advanced age, nonendometrioid tumor type, advanced FIGO
stage, performance of lymphadenectomy, presence of lymph
node metastasis, high FIGO grade, increased depth of myo-
metrial invasion, positive lymphovascular space invasion,
adnexal metastasis, positive peritoneal cytology, omentalTable 1
Clinical, surgical, and pathological characteristics of the entire cohort.
Characteristics
Age at initial diagnosis (y) 58 (23e92)
Tumor size at initial diagnosis (mm) 41 (1e335)
FIGO 2009 stage Stages I & II 1088 (81)
Stages III & IV 257 (19)
FIGO gradea 1e2 1055 (78.4)
3 280 (21)
Treatment Staging surgery performed 827 (62)
Staging surgery not performed 518 (38)
Adjuvant therapy Not performed 752 (56)
Performed 593 (44)
Type of adjuvant therapy Radiotherapy 396 (66.7)
Chemotherapy 112 (19)
Chemotherapy & radiotherapy 83 (14)
Hormonal therapy 2 (0.3)
Data are presented as n (%) or median (range).
FIGO ¼ International Federation of Gynecology and Obstetrics.
a The grade of 10 patients could not be obtained.
Median value.
b Chemotherapy followed by radiotherapy or radiotherapy followed by
chemotherapy or sandwich therapy (3 cycles of paclitaxel and carboplatin
followed by radiotherapy followed by 3 cycles paclitaxel and carboplatin).metastasis, and taking adjuvant therapy were associated with
PR (Table 2). Since lymphadenectomy was performed on
patients with a high risk of lymph node metastasis, advanced
stage disease, nonendometrioid tumor type, deep myometrial
invasion, high FIGO grade, cervical invasion, adnexal
metastasis, lymphovascular space invasion, and positive
peritoneal cytology were more common in these patients.
This was also the case for those who received adjuvant
therapy.
The correlation between prognostic factors was detected
with logistic regression analysis; according to this assessment,
age at diagnosis (58 years vs. > 58 years), FIGO grade
(Grade 1 and 2 vs. Grade 3), lymphovascular space invasion
(negative vs. positive), and stage (Stage I and II vs. Stage III &
Table 3
Multivariate analysis of selected clinicopathological variables regarding pul-
monary recurrence.
Parameter p HR 95% CI
Age at initial diagnosis (58 y vs. >58 y) 0.061 2.207 0.963e5.057
FIGO grade (Grades 1 & 2 vs. Grade 3) 0.077 1.628 0.948e2.798
Lymphovascular space invasion
(negative vs. positive)
0.348 1.531 0.629e3.729
2009 FIGO stage (Stages I & II vs.
Stages III & IV)
0.023 2.842 1.158e6.975
CI ¼ confidence interval; FIGO ¼ International Federation of Gynecology and
Obstetrics; HR ¼ hazard ratio.
Table 4
Clinical and pathological characteristics of patients with pulmonary
recurrence.
Characteristics n % Mean Median (range)
Age at initial diagnosis (y) 62.7 62 (48e81)
Age at recurrence (y) 63.8 63 (48e83)
Disease free interval (mo) 19 17 (1e54)
CA 125 level at initial diagnosis (IU/mL) 149 49 (1e915)
CA 125 level at recurrence (IU/mL) 346 110 (1e3150)
2009 FIGO stage IA 3 8.3
IB 11 30.6
II 2 5.6
IIIA 2 5.6
IIIC1 3 8.3
IIIC2 4 11.1
IVB 11 30.6
Tumor type Endometrioid 24 66.7
Clear cell 4 11.1
Serous 5 13.9
Undifferentiated 2 5.6
Mixed 1 2.8
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stage was found to be an independent prognostic factor for PR
(Table 3). The risk of development of PR was 2.842 times
higher in patients with Stages III and IV disease (95% confi-
dence interval, 1.158e6.975; p ¼ 0.023).FIGO grade 1 4 11.1
2 13 36.13.2. PR group
3 19 52.8
Depth of myometrial
invasion
No invasion 1 2.8
<1/2 7 19.4
1/2a 21 58.3
Serosal invasion 7 19.4
Lymphovascular space
invasion
Negative 12 33.3
Positive 17 47.2
Not reported 7 19.4
Cervical invasion Negative 27 75
Positive 9 25
Peritoneal cytology Negative 28 78.2
Positive 8 22.2
Adnexal metastasis Negative 28 78.2
Positive 8 22.2
Omental metastasis Negative 23 63.9
Positive 10 27.8
Not reportedb 3 8.3
Lymphadenectomy at
initial surgery
Not performed 2 5.6
Performed 34 94.4
No. of harvested lymph nodes 47.3 45 (4e99)
Lymph node metastasis Negative 19 52.8
Isolated pelvic 4 11.1
Isolated paraaortic 5 13.9
Pelvic & paraaortic 6 16.7
Adjuvant therapy at
initial treatment
Not performed 3 8.3
Performed 33 91.7
Type of adjuvant
therapy
Radiotherapy 22 66.7
Chemotherapy 10 30.3
Sandwich therapyc 1 3
FIGO ¼ International Federation of Gynecology and Obstetrics.
a Except for uterine serosal invasion.
b Omentectomy was not preformed.
c Three cycles of paclitaxel and carboplatin followed by radiotherapy fol-
lowed by three cycles of paclitaxel and carboplatin.The median age of the patients with PR at the initial
diagnosis was 62 years, ranging between 48 years and
81 years. Median DFI was 17 months (range, 1e54 months)
and the median age at recurrence was 63 years (range,
48e83 years). Median recurrence tumor size was 27.5 mm
(range, 10e110 mm) and median pulmonary tumor size was
20.5 mm (range, 10e100 mm). Eleven patients had a single
nodule in the lung and 20 patients had multiple nodules. The
data of five patients regarding the number of pulmonary tumor
nodules could not be obtained. Twelve patients had symptoms
at the time of diagnosis of recurrence. The main symptom was
dyspnea in five patients, gastrointestinal symptoms in two
patients, abdominal distension in two patients, coughing in
one patient, vaginal bleeding in one patient, and severe fatigue
in one patient.
The median CA-125 level at initial diagnosis was 49 IU/mL
and ranged between 1 IU/mL and 915 IU/mL. Median CA-125
level at recurrence was 110 IU/mL (range, 1e3150 IU/mL).
Three patients had Stage IA disease, 11 patients had Stage IB
disease, two patients had Stage II, two patients had Stage IIIA,
three patients had Stage IIIC1, four patients had Stage IIIC2,
and 11 patients had Stage IVB disease, according to FIGO
2009 criteria. Twenty-four patients had endometrioid type
carcinoma and 19 patients had FIGO Grade 3 disease. Myo-
metrial invasion was 1/2 in 28 patients, and seven of these
had uterine serosal invasion. Cervical invasion was observed
in nine patients and invasion was stromal in these patients.
Positive peritoneal cytology, lymphovascular space invasion,
adnexal metastasis, and omental spread were detected in eight
patients, 17 patients, eight patients, and 10 patients, respec-
tively. Clinical, surgical, and pathological data at the initial
diagnosis are shown in Table 4 in detail.
Thirty-four patients had lymphadenectomy in the initial
surgery. The median lymph node number harvested in these
patients was 45 (range, 4e99); it was 13 (range, 5e36) for the
para-aortic region and 41 (range, 4e65) for the pelvic region.Among the patients having lymphadenectomy, lymph node
involvement was detected in 15 patients. Lymph node
metastasis was in the paraaortic region in five patients, in the
pelvic region in four patients, and in both regions in six pa-
tients (Table 4). Median metastatic lymph node number was
six and ranged between one and 53.
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surgery. Thirty-three patients received adjuvant therapy.
Among these, 22 had radiotherapy only, 10 had chemotherapy
only, and one had sandwich therapy (3 cycles of paclitaxel and
carboplatin followed by radiotherapy followed by 3 cycles of
paclitaxel and carboplatin). Chemotherapy was applied as
paclitaxel and carboplatin in six patients, cisplatin and adria-
mycin in two patients, adriyamisin in one patient, and dose-
taxel and carboplatin in one patient. Four patients had thoracic
surgery and there was no residual tumor in three of these
patients. Complete clinical response was achieved in three of
these four patients who took chemotherapy following surgery
(2 patients megestrol acetate, 1 patient paclitaxel and carbo-
platin, and 1 patient cisplatin and epirubicin). Stable disease
was obtained in the patient who had residual tumor following
surgery and took megestrol acetate.
Recurrence was isolated PR in 21 (58.3%) patients. Among
the 15 (41.7%) patients with synchronized PR, four had
recurrence in the lung and pelvis, four had recurrence in the
lung and upper abdomen, three had recurrence in the lung and
liver parenchyma, one had recurrence in the lung, liver pa-
renchyma, surrenal gland, and pelvis, one had recurrence in
the lung, upper abdomen, and pelvis, one had recurrence in the
lung and bone, and one had recurrence in the lung, upper
abdomen, bone, and brain.
The patients with synchronized PR had advanced stage
disease at the initial diagnosis compared with patients with
isolated PR (80% vs. 31.1%, respectively; p ¼ 0.013). In this
group, median DFI was shorter (23.5 months vs. 12.7 months,
respectively; p ¼ 0.015). Additionally, lymph node involve-
ment, omental metastasis, and positive peritoneal cytology
were more common in this group (Table 5). However, bothTable 5
Clinical, pathological characteristics, and type of pulmonary recurrence.
Characteristics Isolated pulmonary r
Age at initial diagnosis (y) 63 (61; 53e77)
Age at recurrence (y) 64.8 (62.5; 55e80)
CA 125 level at recurrence (IU/mL) 349 (66.5; 1e1350)
No. of removed lymph nodes 46.1 (48; 4e93)
Disease free interval from initial diagnosis (mo) 23.5 (19; 1e54)
Pulmonary tumor size (mm) 34.2 (25; 10e100)
Recurrence tumor size (mm) 34.2 (25; 10e100)
2009 FIGO Stages III & IV 38.1
Lymph node metastasis 28.6
Omental metastasis 10
Positive peritoneal cytology 9.5
Nonendometrioid tumor type 23.8
FIGO Grade 3 57.1
Depth of myometrial invasion  1/2 81
Positive lymphovascular space invasion 47.1
Cervical invasion 19
Adnexal metastasis 14.3
Adjuvant therapy was performed 95.2
Adjuvant chemotherapy 21.1
Multiple pulmonary nodule 68.4
Data are presented as mean (median; range) or %.
FIGO ¼ International Federation of Gynecology and Obstetrics.groups were similar in terms of age at primary diagnosis, age
at recurrence, CA-125 level at recurrence, number of har-
vested lymph nodes, recurrence tumor size, pulmonary tumor
size, pulmonary nodule number, tumor type, FIGO grade,
depth of myometrial invasion, presence of cervical invasion,
adnexal metastasis, appliance of adjuvant therapy, and type of
adjuvant therapy.
Median follow-up time after PR was 23.5 months (range,
4e108 months). Fifteen patients died. Estimated 2-year OS
was 52% in the study population. Early FIGO stage, no
lymphatic metastasis, negative lymphovascular space invasion,
no cervical invasion, negative adnexal spread, negative peri-
toneal cytology, negative omental metastasis, adjuvant radio-
therapy after initial surgery, isolated pulmonary recurrences,
and chemotherapy at recurrence were associated with improved
survival after PR (Table 6). All these factors associated with
good prognosis were present in eight patients. Median follow-
up time after recurrence was 35 months (range, 6e108 months)
in these patients and none of them died of disease.
The appliance of chemotherapy after initial surgery was
associated with a reduction in OS compared with radiotherapy
(15 months vs. 44 months, respectively; p ¼ 0.020). However,
the patients who received adjuvant chemotherapy were at
advanced stages. Ninety percent of the patients having
chemotherapy and 43.5% of the patients having radiotherapy
had FIGO Stages III and IV disease ( p ¼ 0.013). OS was
poorer in the patients with advanced stage disease. OS was
17 months in patients with Stages III and IV disease, while it
was 55 months in the patients with Stages I and II disease
( p ¼ 0.011). Type of PR was associated with OS. OS was
54 months and 10 months in patients with isolated PR and
synchronized PR, respectively ( p ¼ 0.005; Fig. 1).ecurrence Synchronized pulmonary recurrence p
62.3 (63; 48e91) 0.826
62.4 (63; 48e83) 0.403
344 (300; 2e1205) 0.986
49.3 (43; 5e99) 0.769
12.7 (14; 2e24) 0.015
26 (17; 10e62) 0.387
35 (30; 10e110) 0.770
80 0.013
69.2 0.020
61.5 0.002
40 0.030
46.7 0.151
46.7 0.535
73.3 0.588
75 0.132
33.3 0.329
33.3 0.175
86.7 0.359
42.9 0.178
58.3 0.567
Table 6
Clinical, pathological, surgical factors, and overall survival in patients with pulmonary recurrence.
Characteristics n Overall survival (mo), mean p
Age at initial diagnosis (y)a 62 14 39 0.144
>62 14 24
Age at recurrence (y)a 63 19 34 0.515
>63 15 27
Disease free interval (mo)a 17 19 28 0.976
>17 17 27
2009 FIGO stage I & II 16 55 0.011
III & IV 20 17
Tumor type Endometrioid 24 44 0.086
Nonendometrioid 12 17
Lymphadenectomy at initial
surgery
Not performed 2 e NCb
Performed 34 e
No. of removed lymph node
sa
45 15 43 0.906
>45 14 28
Lymph node metastasis Negative 19 55 0.014
Positive 15 16
FIGO grade 1 & 2 17 40 0.296
3 19 21
Depth of myometrial invasion 1/2 8 26 0.925
>1/2 28 32
Lymphovascular space
invasion
Negative 12 58 0.048
Positive 17 22
Cervical invasion Negative 27 39 0.024
Positive 9 16
Adnexal metastasis Negative 28 44 0.001
Positive 8 7
Peritoneal cytology Negative 28 45 0.008
Positive 8 8
Omental metastasis Negative 23 49 <0.0001
Positive 10 7
Adjuvant therapy at initial
treatment
Not performed 3 e NCc
Performed 33 e
Type of adjuvant therapy at
initial treatment
Radiotherapy 23 44 0.020
Chemotherapy 10 15
Recurrence tumor size (mm)a 28 18 0.706
>28 41
Pulmonary tumor size (mm)a 21 17 0.441
>21 45
Ca 125 at recurrence (IU/
mL)a
110 13 50 0.061
>110 11 13
Symptom at recurrence Negative 24 29 0.431
Positive 12 32
Type of recurrence Isolated pulmonary
recurrence
21 54 0.005
Synchronized pulmonary
recurrence
15 10
No. of pulmonary nodules Single pulmonary nodule 11 30 0.424
Multiple pulmonary nodules 20 40
Pulmonary surgery at
recurrence
Not performed 32 9 0.059
Performed 4 37
Salvage treatment for
recurrence
Radiotherapy 5 13 0.025
Chemotherapy 18 43
FIGO ¼ International Federation of Gynecology and Obstetrics.
a Median value.
b NC ¼ not compared because two patients did not have lymphadenectomy.
c NC ¼ not compared because three patients did not take adjuvant chemotherapy.
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radiotherapy, two patients took megestrol acetate, and 11 pa-
tients were managed palliatively at recurrence. Among the
patients having chemotherapy, seven took paclitaxel and car-
boplatin, four took cisplatin and epirubicin, two took cisplatinand adriamycin, one took carboplatin, one took cisplatin, one
took adriamycin, one took topotecan, and one took paclitaxel,
cisplatin, and farmorubicin. The efficiency of treatment
applied at recurrence was analyzed excluding the patients
taking hormonal therapy and the patients who were managed
Fig. 1. Type of pulmonary recurrence.
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with improved OS. OS was 43 months in the patients taking
chemotherapy, while it was 13 months in the patients who took
radiotherapy ( p < 0.025; Fig. 2).
Endometrioid type tumor and having thoracic surgery
were borderline predictors for improved prognosis
( p ¼ 0.086 and p ¼ 0.059, respectively). CA-125 level at the
time of recurrence had a tendency to be significant to predict
OS ( p ¼ 0.061). However, age at diagnosis and age at
recurrence, DFI, number of harvested lymph nodes, FIGOFig. 2. Treatmentgrade, depth of myometrial invasion, recurrence tumor size,
pulmonary tumor size, number of tumoral nodules in the
lung, and presence of symptoms were not associated with
OS.
4. Discussion
PR developed in 2.7% of 1345 patients whose median
follow-up time was 36 months. In the univariate analysis,
advanced age, advanced FIGO stage, performance ofof recurrence.
219T. Turan et al. / Journal of the Chinese Medical Association 79 (2016) 212e220lymphadenectomy, high FIGO grade, increased depth of
myometrial invasion, positive lymphovascular space invasion,
extrauterine disease (adnexal metastasis, positive peritoneal
cytology, omental metastasis, and lymph node metastasis), and
receiving adjuvant therapy were associated with PR. Only
FIGO stage was an independent prognostic factor for PR
development in logistic regression analysis. PR developed in
7.8% of the patients with Stages III and IV disease and 1.5%
of the patients with Stages I and II disease ( p < 0.0001).
Similar results were reported by Mariani et al.15 In that study,
advanced age (>65 years), advanced stage (Stage IV), deep
myometrial invasion (>1/2), high FIGO grade (Grade 3),
adnexal metastasis, positive peritoneal cytology, lymphovas-
cular space invasion, adjuvant chemotherapy or radiotherapy,
and uterine tumor size were associated with PR in the uni-
variate analysis. However, in the multivariate analysis, only
Stage IVB disease and deep myometrial invasion were inde-
pendent prognostic factors for PR. These results were sup-
ported by other studies.13,17
Two-year OS after recurrence was 52% in the present study.
Survival was associated with FIGO stage, lymphovascular
space invasion, cervical invasion, extrauterine disease at initial
diagnosis (lymph node metastasis, adnexal metastasis, positive
peritoneal cytology, and omental metastasis), type of adjuvant
therapy, site of recurrence (isolated vs. synchronized), and
salvage treatment at recurrence. OS was 44 months and
15 months in the patients who received radiotherapy and
chemotherapy, respectively. Nevertheless, the relationship
between adjuvant therapy and survival depended on what
chemotherapy was given to which patient. The patients who
received chemotherapy were at more advanced stages than the
patients taking radiotherapy. Ninety percent of patients taking
chemotherapy had Stages III and IV disease, while it was
43.5% for the patients who had radiotherapy, and OS was
significantly lower in the patients who had advanced stage
disease. OS was 55 months and 17 months for the patients
with Stages I and II disease and Stages III and IV disease,
respectively. Similar results regarding survival after recurrence
and adjuvant chemotherapy were also reported in the study by
Huang et al6 in which recurrent endometrial cancer was
evaluated. However, in the present study, cytotoxic therapy as
the salvage therapy improved OS in the patients with PR. OS
was 43 months in patients receiving salvage chemotherapy,
while it was 13 months in the patients who received salvage
radiotherapy. However, it must be mentioned that this result
was based on only five patients who received salvage radio-
therapy. Nevertheless, lower FIGO grade, smaller pulmonary
tumor size (2 cm), and the presence of estrogen receptor
were associated with better survival, while salvage chemo-
therapy was related to poorer survival compared with other
treatment modalities in patients with isolated PR in the study
by Dowdy et al.16 In that study, OS was 14 months and
28 months in patients who received chemotherapy and other
treatment modalities, respectively. The authors explained this
result with the presence of poorer prognostic factors in the
patients receiving chemotherapy. However, in the same study,hormonal therapy was shown to be efficient in selected pa-
tients. In the present study, megestrol acetate was given to the
two patients who underwent pulmonary metastasectomy as
salvage therapy. Complete clinical response could be achieved
in the patients who had no residual tumor following the sur-
gery performed for the recurrence 36 months after the initial
therapy and she has been free of disease for 108 months. The
second patient had recurrence 21 months after the initial
therapy and there was gross residual tumor following thoracic
surgery and she has been using megestrol acetate since then.
She has had stable disease for 23 months.
Earlier reports stated a low survival after PR. Bouros et al14
showed that 75% of the patients died of disease in the 1st year
after the diagnosis of PR. However, in that study, in 21% of the
patients with PR who were analyzed, the tumor type was
uterine sarcoma. OS was reported to be 98 months after the
diagnosis of PR in the patients who had low grade tumor only
in the lung, equal or lower than 2 cm in the study by Dowdy
et al.16 Nevertheless, in their study, 2-year OS was found to be
22%. This is much lower than the 2-year OS that we found.
This difference may be explained by the higher rate of pro-
gressive disease during the initial treatment (22% vs. no pro-
gressive disease in our study), the lower rate of isolated PR
(34% vs. 58% in our study), presence of higher rate of
abdominal disease (33% vs. 19.4% in our study), and the
lower DFI in that study (median 9 months vs. 17 months).
In the present study, site of recurrence was important. OS
was significantly lower in the patients with synchronized PR
compared with the patients who had isolated PR (10 months
vs. 54 months, respectively). However, pulmonary tumor size
and number of tumoral nodules in the lung were not associated
with OS. Similar results were also reported by other studies.
OS was 27 months and 7 months in the patients with isolated
PR and synchronized PR, respectively, in the study by Dowdy
et al.16 In that study, pulmonary tumor size was associated
with OS in the patients with isolated PR, while number of
pulmonary tumoral nodules were not. By contrast, Otsuka
et al17 showed that survival after PR was lower in the presence
of extensive pulmonary tumor.
In our study, synchronized PR developed earlier than iso-
lated PR (median DFI 14 months vs. 19 months, respectively),
at more advanced stages (Stages III and IV 80% vs. 38.1%,
respectively), and synchonized PR was observed more
commonly in patients who had lymph node metastasis, posi-
tive peritoneal cytology, and omental metastasis compared
with patients having isolated PR. These results were similar to
the results of the study by Dowdy et al.16 Additionally, in that
study, adnexal metastasis and nonendometrioid tumor type
were more common in the patients with synchronized PR.
Although the type of PR (synchronized vs. isolated) was
associated with DFI in both studies, it was not associated with
survival after recurrence. However, Otsuka et al17 reported that
DFI was associated with OS (24 months vs. > 24 months).
Other studies also showed that DFI was associated with sur-
vival after recurrence in patients with endometrial
cancer.18,19,21,23
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cance for OS. OS was 37 months and 9 months in patients who
had resection and those who did not, respectively. Neverthe-
less, it should be kept in mind that this was the result of only
four patients who had thoracic surgery. Similarly, in other
studies, pulmonary metastasectomy was shown to be associ-
ated with survival.18e21 In the study by Anraku et al,18 they
analyzed 133 patients who had metastasectomy for uterine
tumor related PR and the 5-year OS was 76% in the 23 pa-
tients whose primary site were endometrium. However, this
superior survival could not be shown by Calvero et al.21 In that
study, 3-year OS after thoracic surgery for PR was 28% in
patients with endometrial cancer.
The retrospective nature of the present study resulted in
bias in patient selection. Additionally, it prevented the ho-
mogenization of the patient population. The small number of
patients was another limitation. However, the present study is
one of the few studies that analyzed only the patients with PR
in detail. Furthermore, this was a study that evaluated the
largest number of patients in 20 years.
In conclusion, in the presence of poor clinical, surgical, and
pathological factors at initial diagnosis, it should be known
that PR may develop. In this cohort, 50% of who survive for at
least 2 years, systemic therapy should be performed after
recurrence and thoracic surgery should be kept in mind for
selected patients. However, multi-center studies are required
for the standardization of the treatment that will be performed
after PR.
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